We demonstrated that allantoin, a terminal oxidation product of UA, not only serves as a biomarker of oxidative stress in individuals with metabolic disorders but also functions as a risk factor that directly promotes MASLD progression by disrupting PPARα regulated TG and TC metabolism. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.